Skip to content
lifestyle.thenyctimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
CONNECTA Therapeutics
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
September 10, 2026
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
June 10, 2026